PMID int64 27.8M 36.2M | Title/Abstract stringlengths 7 10.7k | MeshTerms stringlengths 7 104 | SemanticTypes stringlengths 4 84 |
|---|---|---|---|
34,688,492 | urinari contin dispar patient anorect malform fecal incontin primari concern mani children anorect malform arm urinari incontin also preval popul racial ethnic socioeconom dispar urinari contin observ condit previous evalu arm aim evalu urinari contin associ demograph socioeconom characterist individu arm | D000071056;D005242;D014549 | T047;T184;T046;T190;T019 |
34,688,491 | australian foster carer view support matern breastfeed attach home care breastfeed support infant health growth develop promot matern attach sensit caregiv matern separ due child protect concern result termin breastfeed associ advers outcom preserv breastfeed infant place home care issu concern | D001942;D006699 | T040;T058;T055 |
34,688,485 | cross section studi sar cov seropreval among asymptomat healthcar worker tertiari healthcar centr assess impact ppe guidelin present studi estim seropreval sar cov among asymptomat hcws assess impact various categori ppe | D000086382;D006282 | T097;T047;T067 |
34,688,483 | opioid prescript bone metastat cancer patient cross section nationwid pharmacoepidemiolog studi oncolog situat repres major palliat situat label palliat stage often come late oncolog pain come first among discomfort symptom greatest impact qualiti life wonder whether evolutionari stage cancer link prescript opioid analges observ prescript strong opioid patient suffer metastat bone cancer month identifi situat palliat cross section observ studi perform januari decemb use data french nationwid claim databas includ patient cancer least one metastat bone locat palliat situat seventeen percent n patient prescript opioid analges palliat care label n prescript n prescript prescript opioid analges increas dosag opioid analges observ label stage diseas palliat averag dosag rang mg per day studi show label situat palliat affect prescript strong opioid analges earli identif situat palliat essenti provid appropri care | D010166 | T061 |
34,688,480 | manag stroke patient antithrombot therapi practic issu era direct oral anticoagul antithrombot drug ad mainstay secondari prevent thrombot vascular diseas manag patient long term treatment ad admit acut cerebrovascular diseas either ischem stroke intracerebr hemorrhag ich becom frequent situat might influenc decis make process diagnosi therapeut strategi aim review summar current data literatur help clinician decis stroke care patient take ad larg bodi data made possibl codifi manag patient present ich antiplatelet drug vitamin k antagonist increas use direct oral anticoagul doa futur develop new antiplatelet drug rais new problem develop rapid assess tool measur specif biolog activ revers agent dedic class doa make possibl optim individu therapeut strategi review highlight main step ich manag earli identif ad use dedic biolog assay stepwis strategi appli revascular revers therapi final resumpt ad focus individu clinic radiolog characterist person care | D005343;D020521 | T047;T121 |
34,688,478 | effect mastic simul phase transform posterior unit monolith zirconia fix dental prosthes monolith zirconia restor direct expos cyclic load temperatur chang oral caviti cement stress may reduc long term success materi caus uncontrol phase transform within zirconia | D002516;D003764 | T122;T073 |
34,688,471 | corticostriat activ drive compuls reward seek activ mesolimb dopamin system posit reinforc repeat activ individu develop compuls reward seek behavior core symptom addict howev under neural mechan remain elus | D011678;D012201 | T041;T078 |
34,688,470 | observ studi link interest disclosur congress general medicin franc link interest french physician attend medic opinion leader repres market tool whose effect well document franc worldwid less distrust pharmaceut repres trust declin declar tie franc public databas transpar sant present financi tie profession health industri sinc tie must declar begin public intervent sinc improv transpar healthcar stakehold | D030881;D010820 | T097;T055 |
34,688,469 | bioactiv sesquineolignan twig litsea cubeba continu search biolog natur product structur divers tradit chines herb five new sesquineolignan isol ethyl acet extract twig litsea cubeba structur elucid base ms nmr spectroscop data well experiment electron circular dichroism ecd spectra compound show moder inhibitori effect lps induc product raw macrophag ic valu moll respect | D032862 | T002 |
34,688,468 | transcriptom profil human erythroleukemia cell respons sargassum fusiform polysaccharid structur analysi sargassum fusiform fusiform use ingredi chines herbal medicin thousand year howev limit number studi concern therapeut mechan high perform gel permeat chromatographi hpgpc analysi show averag molecular weight fusiform polysaccharid sfps kda sfps compos mannos rhamnos galactos xylos glucos fucos molar ratio configur present research evalu anti tumor potenti fusiform polysaccharid human erythroleukemia hel cell vitro explor sfps apoptosi mechan hel cell transcriptom analysi perform hel cell incub sfps inhibitori effect sfps hel cell growth also analyz found sfps inhibit hel cell prolifer reduc cell viabil concentr depend manner induc insignific toxic effect normal human embryon lung mrc cell compar control group transcriptom analysi identifi total differenti express gene deg includ regul gene regul gene gene ontolog go kyoto encyclopedia gene genom kegg enrich analys perform deg go term pathway found signific enrich final deg random select confirm quantit real time polymeras chain reaction qrt pcr moreov sfps regul pikakt signal transduct pathway result provid framework understand effect sfps cancer cell serv resourc delin anti tumor mechan fusiform | D004915;D044647 | T204;T191 |
34,688,467 | danshen chuanxiongqin inject attenu cerebr ischem stroke inhibit neuroinflamm via tlr tlr myd nf b pathway tmcao mice danshen chuanxiongqin inject dci common use tradit chines medicin treatment cerebr ischem stroke china howev under mechan remain complet understood current studi design explor protect mechan dci cerebr ischem stroke integr whole transcriptom sequenc coupl network pharmacolog analysi first use mous model cerebr ischem stroke transient middl cerebr arteri occlus tmcao found dci mlkg signific allevi cerebr ischem infarct neurolog deficit patholog injuri hippocamp cortic neuron mice next whole transcriptom sequenc perform brain tissu cerebr ischemia diseas cid network construct integr transcriptom sequenc data cerebrovascular diseas relat gene result show cid network imbalanc due tmcao recoveri regul observ dci treatment pathway analysi key gene recoveri effici show neuroinflamm signal pathway high enrich tlrtlr myd nf b pathway predict affect consist vivo valid experi confirm dci exhibit protect effect cerebr ischem stroke inhibit neuroinflamm via tlrtlr myd nf b pathway interest dci mark suppress neutrophil infiltr brain parenchyma via choroid plexus rout show anti neuroinflamm effect conclus result provid depend evid inhibit neuroinflamm via tlrtlr myd nf b pathway main mechan dci cerebr ischem stroke mice | D002545;D000083242;D020521 | T047;T046 |
34,688,466 | investig metabolit five major constitu berberi amurensi normal pseudo germ free rat berberi amurensi berberidacea tradit chines medicin often use treat hypertens inflamm dysenteri enter contain alkaloid main includ berberin berbamin magnoflorin jatrorrhizin palmatin berberi amurensi extract bae often oral taken oral herb might metabol intestin bacteria small intestin howev interact herb gut microbiota still unknown current studi uplcq tof msms combin metabolitepilot peakview softwar use identifi metabolit bae anti biotic cocktail induc pseudo germ free rat normal rat result total metabolit normal rat detect main metabol pathway includ demethyl dehydrogen methyl hydroxyl sulfat glucuronid metabolit exist pseudo germ free rat dehydrogen metabolit methyl metabolit metabolit detect pseudo germ free rat result impli intestin bacteria influenc metabol bae furthermor investig might contribut understand metabol bae promot clinic applic | D000470;D028142;D004365 | T121;T002;T109;T123;T131 |
34,688,465 | tripterygium wilfordii multiglycosid induc hepatotox via inflamm apoptosi zebrafish tripterygium wilfordii multiglycosid gtw common use compound treatment rheumatoid arthriti ra immun diseas clinic practic howev induc liver injuri mechan hepatotox still clear studi design investig gtw induc hepatotox zebrafish larva explor mechan involv hpf hour post fertil zebrafish larva administ differ concentr gtw three day mortal malform rate morpholog chang liver transaminas level histopatholog chang liver zebrafish larva detect revers transcript polymeras chain reaction rt pcr use examin level microrna mir gene relat inflamm apoptosi cell prolifer liver function result show gtw increas mortal zebrafish larva signific malform liver damag occur main manifest elev level alanin aminotransferas alt aspart aminotransferas ast signific liver atrophi vacuol liver tissu spars cytoplasm unclear hepatocyt contour rt pcr result show express mir signific decreas gtw mrna level inflamm relat gene il il tnf il cox ptges signific increas mrna level tgf signific decreas mrna level apoptosi relat gene caspas caspas signific increas mrna level bcl signific decreas mrna level cell prolifer relat gene top uhrf signific reduc mrna level liver function relat gene alr cypc signific increas mrna level cypa signific decreas zebrafish gtw caus increas inflamm enhanc apoptosi decreas cell prolifer abnorm express liver function relat gene lead abnorm liver structur function result hepatotox | D056486;D029757 | T047;T002;T037 |
34,688,464 | therapeut effect neohesperidin tnf stimul human rheumatoid arthriti fibroblast like synoviocyt pathogensi rheumatoid arthriti ra activ ra fibroblast like synoviocyt ra flss combin similar prolif featur tumor inflammatori featur osteoarthr eventu lead joint eros therefor imper research develop new compound effect inhibit abnorm activ ra flss retard ra progress neohesperidin neo major activ compon flavonoid compound anti inflamm anti oxid properti studi anti inflamm anti migrat anti invas anti oxid apoptosi induc effect neo ra flss explor investig under mechan result suggest neo decreas level interleukin il il il tnf mmp mmp mmp flss moreov neo block activ mapk signal pathway furthermor treatment neo induc apoptosi flss inhibit migrat flss also found neo reduc accumul reactiv oxygen speci ros induc tnf taken togeth result highlight neo may act potenti promis therapeut drug manag ra | D001172;D000070918 | T025;T047 |
34,688,463 | physalin b reduc secret regul bace express activ foxo inhibit stat phosphoryl physalin b pb one major activ steroid constitu solanacea physali plant wide varieti biolog activ found pb signific regul amyloid secret naappsw cell howev under mechan well understood current studi investig chang key enzym involv amyloid precursor protein app metabol app metabolit treat naappsw cell pb differ concentr result indic pb reduc secret caus regul secretas bace express indic protein mrna level research reveal pb regul bace express induc activ forkhead box foxo inhibit phosphoryl signal transduc activ transcript stat addit effect pb bace express secret revers treatment foxo sirna stat antagonist si conclus data demonstr pb effect regul express bace reduc asecret activ express foxo inhibit phosphoryl stat | D000544;D053829 | T048;T047;T116;T126 |
34,688,462 | effect chitooligosaccharid zinc ovarian function mice prematur ovarian failur via sesnnrf signal pathway chitooligosaccharid zinc coszn power anti oxid anti age scaveng whose anti oxid abil immens exceed vitamin c therefor studi aim investig protect effect coszn prematur ovarian failur pof potenti mechan femal km adult mice divid follow group treatment group mgkg coszn treatment group mgkg coszn prevent group two control group two cybus group coszn mgkg coszn mgkg therapeut prevent administ pof mice treatment prevent studi respect group administ day fewer primari secondari follicl observ coszn treat group includ treatment prevent group control group meanwhil ovarian index level fsh lh notabl increas treatment prevent group compar cybus group level mvh oct pcna treatment group kg coszn mvh prevent group remark increas compar cybus group meanwhil level p p protein regul treatment prevent group compar cybus group addit amount sestrin sesn sod protein obvious higher treatment group mgkg coszn cybus group similar amount nrf sesn protein regul prevent group besid increas gsh level observ two treatment group compar cybus group trend also present prevent group taken togeth coszn improv ovarian follicular develop regul sesnnrf signal pathway result suggest role coszn novel agent treatment prevent pof | D016649 | T047 |
34,688,451 | smoke cessat advic dental care profession associ smoke status analysi nation health nutrit examin survey smoke remain major contributor mortal morbid dental care profession posit help patient quit smoke result clinic trial shown efficaci dental care profession smoke cessat advic howev evid effect general popul unit state limit author examin associ smoke cessat advic dental care profession quit behavior adult smoker general popul | D003376;D016540 | T058;T055 |
34,688,434 | infect vaccin sar cov lead last immun mani nation pursu rollout sar cov vaccin exit strategi unpreced covid relat restrict howev success strategi reli critic durat protect immun result natur infect vaccin sar cov infect elicit adapt immun respons larg breadth viral epitop although durat respons vari age diseas sever current evid case studi larg observ studi suggest consist research common respiratori virus protect immunolog respons last approxim month primari infect reinfect like given insuffici robust primari humor respons marker humor cell mediat immun memori persist mani month might help mitig sever diseas upon reinfect emerg data includ evid breakthrough infect suggest vaccin effect might reduc signific emerg variant concern henc secondari vaccin need develop maintain popul level protect immun nonetheless intervent also requir outbreak like occur due antigen drift select pressur novel variant global popul mobil | D000086382;D007156;D000087507 | T081;T047;T042;T067 |
34,688,422 | treat chronic diseas obes obes treatabl chronic diseas primari care provid play essenti role diagnosi treatment comprehens care patient obes recent year treatment approach rapid evolv increas effect safe therapi review provid practic inform care patient obes focus antiobes pharmacotherapi within context current avail therapeut modal intens lifestyl intervent bariatr surgeri | D008019 | T047;T054 |
34,688,413 | decis make subclin thyroid diseas subclin thyroid diseas frequent encount clinic practic although overt thyroid dysfunct associ advers clinic outcom uncertainti remain implic subclin thyroid diseas avail data suggest subclin hypothyroid may associ increas risk cardiovascular diseas death despit find treatment thyroid hormon consist demonstr reduc cardiovascular risk subclin hyperthyroid associ increas risk atrial fibril osteoporosi associ cardiovascular diseas death uncertain decis treat depend degre thyroid stimul hormon suppress under comorbid | D000066491 | T060 |
34,688,409 | possibl role pai blockad melanoma immunotherapi new articl journal investig dermatolog tseng et al confirm sensit melanoma cell antipd l checkpoint inhibitor therapi correl high pd l surfac express block pd l membran clear control lrp pai express high cell surfac level pd l maintain | D008545;D017395 | T191;T116;T123 |
34,688,408 | treat psoriasi light touch although sever anticytokin antibodi inhibitor avail treatment psoriasi effect better toler altern would interest articl journal investig dermatolog michiel et al propos new strategi target altern activ pathway il receptor attenu murin psoriasi like skin inflamm without affect il depend barrier defens gut | D003872;D011565 | T047 |
34,688,407 | make lemonad put wisdom genom work atop dermat get gwas hit action gene remain challeng complex diseas genet new articl journal investig dermatolog sobczyk et al use wide varieti genom data generat priorit algorithm tackl problem atop dermat call wisdom genom generat promis result | D003876;D004485 | T047 |
34,688,406 | regul calcium sens receptor keratinocyt skin age mice human impair function calcium sens receptor casr import skin contribut sever epiderm function includ differenti water permeabl barrier repair wound heal celli et al show casr level reduc keratinocytesskin age individu result impair key function casr agonist correct defect suggest possibl therapi combat age relat delay skin wound heal | D012879 | T070;T042 |
34,688,398 | current status patient report outcom measur vascular surgeri previous publish review focus generic diseas specif patient report outcom measur prom relev vascular surgeri limit arteri condit object project identifi avail prom relev diseas treat vascular surgeon evalu vascular surgeon percept barrier widespread implement concern regard prom provid overview prom develop summar current avail prom specif vascular surgeon also report result survey societi vascular surgeri member serv committe within polici advocaci council address barrier facilit use prom clinic practic final report qualit result two focus group conduct assess granular percept prom prepared vascular surgeon widespread implement prom focus group identifi lack awar exist prom knowledg prom develop valid clariti around prom use clinician main subthem barrier prom implement clinic practic | D057510;D000071066;D011788;D014656 | T170;T061;T078 |
34,688,388 | urinari dickkopf kidney injuri patient chronic pulmonari diseas dickkopf relat protein stress induc epitheli cell deriv glycoprotein promot prognost well predict urinari biomark acut chronic kidney diseas schunk et al provid evid dickkopf relat protein identifi patient chronic obstruct pulmonari diseas preserv kidney function increas risk loss estim glomerular filtrat rate deterior pulmonari function experiment data highlight dickkopf relat protein relat pathophysiolog similar interact chronic kidney diseas chronic obstruct pulmonari diseas | D058186;D008171;D051436 | T047;T037 |
34,688,387 | telomer length chronic kidney diseas caus consequ telomer length consid clock mirror age influenc oxid stress inflamm condit high preval patient chronic kidney diseas degen disord cardiovascular diseas howev discuss controversi whether short telomer causal associ chronic kidney diseas whether chronic kidney diseas contribut attrit telomer length park et al issu kidney intern use extend sampl mendelian random analysi larg data set shed new light research question | D051436;D016615 | T026;T047 |
34,688,386 | gain understand podocyt loss podocyt loss key element under glomerulosclerosi various mechan propos cell loss includ local hemodynam effect local stress cell hemodynam chang togeth may contribut detach podocyt lead sclerosi eleg studi base classic observ add state art imag model intravit microscopi ultrastructur geometri analys provid new insight potenti mechan injuri loss key cell | D005923;D007674;D050199 | T025;T047 |
34,688,385 | keton bodi back place sun keton bodi strong negat imag medicin ketoacidosi life threaten complic diabet howev fang et al report keton bodi exert antisenesc effect podocyt diabet condit via activ nuclear factor e relat factor relat antioxid stress pathway recent progress research longev benefici effect keton bodi clarifi posit imag keton bodi gradual begin develop mani research field includ nephrolog | D016883;D007657 | T047;T109;T123 |
34,688,376 | prior infect sar cov boost broaden adcov immunogen variant depend manner johnson johnson adcov singl dose vaccin repres attract option coronavirus diseas covid vaccin countri limit resourc examin effect prior infect differ sar cov variant adcov immunogen compar particip sar cov naiv either infect ancestr dg virus infect second wave beta predomin prior infect signific boost spike bind antibodi antibodi depend cellular cytotox neutral antibodi dg beta delta howev neutral cross reactiv vari wave robust cd cd cell respons induc vaccin regardless prior infect cell recognit variant larg preserv apart reduct cd recognit delta thus adcov vaccin infect could result enhanc protect covid impact infect variant neutral breadth vaccin implic design second generat vaccin base variant concern | D014611 | T061 |
34,688,371 | borderlin person disord borderlin person disord bpd mental disord high burden patient famili member health care system condit previous regard untreat progress understand manag result earlier diagnosi better treatment outcom coher syndrom bpd typic onset adolesc age year bpd often preced co develop symptom internalis disord depress anxieti externalis disord conduct problem hyperact substanc use bpd associ various poor outcom includ low occup educ attain lack long term relationship increas partner conflict sexual risk take low level social support low life satisfact increas servic use psychotherapi main treatment bpd drug treatment indic comorbid condit requir medic crisi psychosoci intervent insuffici awar bpd non specialist well specialist key appropri earli intervent | D001007;D001883;D003863;D011613 | T061;T048;T184;T041 |
34,688,369 | studi mirtazapin agit behaviour dementia symbad randomis doubl blind placebo control trial agit common peopl dementia negat affect qualiti life peopl dementia carer non drug patient centr care first line treatment need treatment care effect current evid spars safer effect altern antipsychot assess efficaci safeti mirtazapin antidepress prescrib agit dementia | D014151;D000078785 | T039;T121;T109 |
34,688,354 | co benefit sustain dietari shift popul environment health assess larg european cohort studi unhealthi diet rise non communic diseas declin health planet high intertwin food product consumpt major driver increas greenhous gas emiss substanti land use advers health cancer mortal assess potenti co benefit shift sustain diet aim investig associ dietari greenhous gas emiss land use caus caus specif mortal cancer incid rate | D004032;D000074382 | T168;T197 |
34,688,334 | overexpress mir load restrain develop cervic cancer regul frizzl class receptor fzd liposom nanoparticl carrier dysregul express mir note correl progress cervic cancer studi attempt investig impact overexpress mir load liposom nanoparticl prolifer cervic cancer cc provid insight pathogenesi cc disord cc cell co cultur pure liposom nanoparticl empti vector group mir agonist load liposom nanoparticl transfect mir antagonist besid cell expos tgf smad signal pathway inhibitor activ whilst cell prolifer assess mtt assay express fzd mir determin western blot analysi carri detect express tgf pathway factor tgf smad smad p smad downstream smad pathway interact mir fzd evalu dual luciferas report gene assay overexpress mir induc arrest gg phase cell cycl elev smad protein express p lower express tgf smad p smad fzd transfect mir inhibitor exhibit opposit activ presenc mir agonist load liposom nanoparticl induc decreas cell prolifer target relationship mir fzd administr tgf smad agonist result increas mir smad express well decreas tgf smad p smad fzd protein express number phase gm phase cell p signal inhibitor opposit suppress cell prolifer decreas mir express mir load liposom nanoparticl activ tgf smad signal pathway restrain cell cycl suppress cell divis prolifer target fzd cc molecular mechan relat activ tgf smad signal pathway | D035683;D053758;D002583 | T191;T114;T073;T123 |
34,688,333 | umbil cord mesenchym stem cell exosom allevi progress kidney failur modul inflammatori respons oxid stress ischemia reperfus mice model efficaci stem cell treatment renal failur wide recogn howev excess volum stem cell block capillari thus potenti risk ignor stem cell exosom secretori extracellular vesicl size nm similar function stem cell much smaller size studi aim investig role human umbil cord mesenchym stem cell ucmsc deriv exosom treatment renal failur caus ischemia reperfus fifti week old femal c mice underw bilater renal ischemia reperfus surgeri minut week treat group receiv ucmsc deriv exosom treatment control group sole inject amount pbs age week kidney function kidney damag inflammatori respons oxid stress measur moreov effect ucmsc deriv exosom phenotyp macrophag also test result show ucmscsderiv exosom signific reduc level blood urea nitrogen bun serum creatinin scr urinari albumin creatinin acr isoprostan ucmsc deriv exosom also improv atrophi kidney glomerulus decreas kidney pro inflammatori factor express mrna ii ii tnf mcp oxid stress malondialdehyd increas glutathion level howev f immunohistochemistri show signific differ two group system inflamm measur ucmsc deriv exosom decreas proinflammatori factor tnf il il level increas anti inflammatori factor il level vitro experi show ucmsc deriv exosom decreas protein express level tnf increas protein express level il macrophag ucmsc deriv exosom reduc kidney inflamm oxid stress improv system inflamm thus reduc kidney damag improv kidney function studi show potenti applic valu exosom treatment renal failur | D055354;D059630;D051437 | T026;T047;T025 |
34,688,332 | ophthalm deliveri riboflavin load nanoparticul suspens keratoconus preclin studi rabbit model present investig undertak formul nanoparticul suspens riboflavin treat keratoconus diseas appli infect mice cornea nanoparticl riboflavin prepar use singl solvent evapor method later formul suspens use continu probe sonic method riboflavin nanoparticl suspens evalu various paramet nanoparticl show smooth spheric surfac vitro drug releas drug content found suspens found visual clear ph rang drug entrap found sinc hemolyt activ formul suitabl ophthalm administr draiz test confirm non irrit non itchi natur formul prepar formul nanoparticul gel suspens found signific efficaci experiment anim | D007640;D053758 | T047;T073 |
34,688,331 | graphen quantum dot molecular radiotherapi radiolabel graphen quantum dot radium ra show potent effect bone cancer necess new drug special attent therapi cancer increas day despit properti alpha therapeut radiopharmaceut especi base use radium ra good choic due highest differenti cytotox low advers effect higher bioaccumul tumor site use graphen quantum dot carrier ra promis approach sinc graphen quantum dot low toxic high biocompat adequ size tumor penetr studi develop character radiolabel ra evalu vitro vivo graphen quantum dot radiolabel radium ra bone cancer result show ra incorpor graphen quantum dot follow fajan paneth hahn law cell viabil show potent effect osteosarcoma cell mg sao lower effect normal fibroblast cell hfb corrobor preferenti target also result show promin effect mg sao cell corrobor target undifferenti cell vivo result demonstr renal excret associ fecal excret accumul bone result corrobor efficaci ragqd open new perspect use use ragqd sever diseas | D001859;D006108;D012516;D045663;D011883 | T191;T121;T073;T109;T196 |
34,688,330 | chitosan nanoparticl load tgf inhibit cervic cancer cell progress regul microrna activ tim pathway chemic modifi chitosan nanoparticl nps capabl releas substanc target cell tissu improv microenviron promot wound heal studi aim explor molecular mechan under chitosan nps load tgf particip cervic cancer cc progress tgf load chitosan nps prepar particl size distribut zeta potenti encapsul effici nps determin mtt assay assess toxic nps macrophag cc cell co cultur tgf load chitosan nps experiment group pure chitosan nps control group cell cultur alon produc control group treatment flow cytometri conduct detect apoptosi cycl cancer cell migrat evalu transwel assay mir tim express determin ratio chitosan tgf particl size nm smallest high encapsul rate low potenti np toxic increas concentr rose relat cell prolifer rate indic non toxic cc tissu posit express cd tgf p treatment tgf load chitosan nps induc increas apoptosi rate reduc migrat invad cell caus cell accumul phase compar blank control group p besid experiment group exhibit lower express mir higher express tim higher blank group control group optim concentr ratio produc tgf load chitosan nps less toxic composit nps suppress malign characterist cc cell regul mir activ tim signal pathway surfac macrophag promot secret macrophag inflammatori factor | D048271;D035683;D053758;D002583 | T191;T121;T073;T109;T123;T114 |
34,688,329 | multifunct zinc oxidesilv bimetal nanomateri load nanofib enhanc tissu regener wound heal nativ skin repair requir wound care product protect wound bacteri infect also acceler wound closur minim scar nanomateri wide appli wound heal due multifunct properti previous studi prepar character electrospin zinc oxidesilverpolyvinylpyrrolidonepolycaprolacton znoagpvppcl nanofib use zno ag nanoparticl evalu antibacteri effect vitro work character studi perform confirm znoag nanoparticl physic embed even distribut znoagpvppcl nanofib enabl sustain releas ag zn addit bimetal nanofib show satisfactori fluid handl flexibl vivo wound heal histolog studi show znoagpvppcl nanofib better anti inflammatori skin tissu regener wound heal effect monometal nanofib commerci avail wound plaster yunnan baiyao therefor znoagpvppcl bimetal nanofib may safe effici biomed dress wound heal | D053768;D057139;D015034 | T121;T073;T197 |
34,688,328 | cooh termin silicon quantum dot high effici drug nanocarri target tumor cell imag fluoresc silicon quantum dot siqd character except photost colloid robust well benefici biocompat fast becom new pharmaceut nanocarri view effici load cisplatin cddp onto siqd carboxyl group cooh termin siqd imper chelat format cddp work employ facial microwav irradi rout rapid synthes high qualiti cooh siqd use aminopropyl trimethoxi silan aptm molecul fulfil role silicon precursor maleic acid agent facilit reduct siqd show blue fluoresc associ photoluminesc quantum yield plqi size small nm long last stabil extens rang ph concentr electrolyt reach molar solut sodium chlorid nanocarri carboxyl acid chelat generat high load cddp onto siqd drug load capac dlc ph drug releas cddp ph furthermor mtt assay demonstr non low cytotox siqd role control releas siqd cddp final prepar siqd cddp use cell imag target label tumor folic acid fa conjug characterist allow deploy siqd high effici nanocarri facilit deliveri clinic drug futur | D004364;D045663 | T121;T073 |
34,688,327 | prepar antibacteri perform electrocatalyt zinc oxid nanoparticl divers morpholog studi exploit potenti zinc oxid nanoparticl zno nps divers morpholog catalyst antibacteri agent spheric zno nps rod shape zno nps flower shape zno nps prepar microemuls method solvent heat method hydrotherm method respect structur character sampl investig x ray diffract xrd scan electron microscopi sem techniqu xrd result reveal format spheric zno nps rod shape zno nps flower shape zno nps wurtzit crystal structur sem result show spheric zno nps averag particl size nm rod shape zno nps nm long nm wide obvious hexagon crystal flower shape zno nps three dimension appear obvious petal result electrochem hydrogen evolut reaction experi reveal spheric zno nps exhibit highest electrocatalyt activ lowest potenti voltag due largest specif surfac area antibacteri properti zno nps sampl studi optic densiti method disc diffus method sampl antibacteri effect e coli flower shape zno nps show best antibacteri activ due largest surfac area comparison spheric zno nps rod shape zno nps promis maximum zn releas bactericid mechan regist case differ zno nps morpholog | D053768;D053758;D015034 | T121;T073;T197 |
34,688,326 | strontium load nanotub ti nb zr sn alloy biomed implant ti nb zr sn ti alloy relat low elast modulus uniqu mechan properti desir materi oral implant current studi multifacet strontium incorpor nanotub coat fabric ti alloy ti ntsr anod hydrotherm procedur vitro ti ntsr specimen demonstr better osteogen properti favor osteoimmunomodulatori abil moreov macrophag ti ntsr specimen could improv recruit osteogen differenti osteoblast vivo dens clot high branch thin fibrin small pore exist ti ntsr implant earli stage surgeri analysi deposit ca p element hard tissu slice bone implant contact rate bic ti ntsr implant also show superior osseointegr taken togeth result demonstr ti ntsr coat may maxim clinic outcom ti alloy implant applic | D043942;D013324 | T196;T121;T073 |
34,688,325 | evalu apigenin inhibit lactat dehydrogenas activ base cdte quantum dot fluoresc lactat dehydrogenas ldh one key enzym glucos metabol pathway play critic role cell metabol inhibit ldh inhibit glycolysi process therebi inhibit occurr develop tumor cell two kind ldh inhibitor apigenin emodin obtain test ic sever natur product ldh enzym reaction ic apigenin ldh inhibitor sodium oxal new method evalu perform ldh inhibitor base cdte qds establish time provid new idea research ldh enzym inhibitor | D019187;D045663 | T073;T197 |
34,688,324 | design stabil improv pectin base red blood cell mimick microcapsul oxygen therapeut pectin oligochitosan microcapsul system recent develop novel oxygen therapeut design improv stabil pectin oligochitosan microcapsul physiolog condit coval glutaraldehyd noncoval mn ca cross linker test chemistri morpholog microcapsul studi use ftir sem respect result show glutaraldehyd effect cross linker even low concentr short incub time glutaraldehyd cross link negat impact morpholog microcapsul moreov confirm hemoglobin could retain within microcapsul minim releas | D010100;D010368 | T109;T121;T196;T123 |
34,688,323 | nanobead base screen method antibodi pair dengu virus nonstructur protein dengu fever classic mosquito viral diseas dengu virus non structur protein membran associ homolog dimer anchor surfac infect cell also secret blood nonstructur protein level relat diseas sever presenc nonstructur protein secret cell serum peopl infect dengu virus earli marker infect pair antibodi key establish rapid detect technolog studi prepar recombin nonstructur protein protein dengu virus serotyp purifi prokaryot express prepar monoclon antibodi cell fusion method pair antibodi screen establish base n hydroxi succinimid nanobead prepar monoclon antibodi simpl rapid point care system integr pair antibodi later flow assay establish verifi screen antibodi pair result confirm antibodi pair screen method base n hydroxi succinimid nanobead feasibl | D003715;D003716 | T047;T005 |
34,688,322 | compar toxic biodistribut excret ultra small gold nanoclust differ emiss wavelength exponenti increas use gold nanoclust diagnosi treatment rais serious concern potenti threat live organ howev mechan toxic gold nanoclust vitro vivo remain poor understood work compar toxic studi includ biodistribut excret carri mild chemic synthes ultra small l histidin protect bovin serum albumin bsa protect gold nanoclust aqueous process nanoclust induc remark impact cell viabil even relat high concentr gml haemolyt assay demonstr gold nanoclust could destroy blood cell gml intraven inject mice biocompat biodistribut excret determin quantit analysi result show accumul vari liver spleen kidney lung though primarili liver spleen excret urin faec main excret urin studi obvious abnorm found bodi weight behavior chang blood serum biochem indic histopatholog find suggest gold nanoclust show similar effect vivo safe biocompat lay foundat safe biomed applic futur | D006046;D053768 | T121;T073;T196 |
34,688,321 | new recombin fibronectincadherin protein hydrophob modifi glycol chitosanpaclitaxel layer layer self assembl strategi postop therapi osteosarcoma correl bone injuri osteosarcoma one aggress cancer great threaten health adolesc surgeri difficult resect whole piec tumor tissu residu tumor cell might prolifer tumor site invad blood circul lead tumor recurr metastasi besid invas tumor cell could also lead bone injuri design recombin fibronectin cadherin fusion proteinhydrophob modifi glycol chitosan ptx nanoparticl rfn cdhhgc ptx layer layer self assembl polym base biphas calcium phosphat ceram bcp bcp pei rfncdh ptxhgc n rfncdh sem ftir xps contact angl experi prove success synthesi polym chemotherapi drug ptx bone repair relat rfncdh fusion protein could stabli releas within one week vitro experi exhibit efficaci polym kill residu tumor cell promot prolifer osteoblast confirm polym superior materi postop osteosarcoma therapi | D001859;D048271;D053758;D012516 | T191;T121;T073;T109 |
34,688,320 | atorvastatin atv load lipid bilay coat mesopor silica nanoparticl enhanc therapeut efficaci acut kidney injuri background acut kidney injuri aki increas risk chronic kidney diseas atorvastatin atv load lipid bilay coat mesopor silica nanoparticl l amsn synthes physicochem paramet character l amsn exhibit excel stabil increas size time indic lipid membran coat prohibit mesopor silica nanoparticl msns coalesc result rate drug releas differ signific amsn l amsn test time point remark improv hydrogen peroxid ho treat human umbil vein endotheli cell huvec viabil observ treatment l amsn malondialdehyd mda level signific reduc compar control cell extent apoptosi control ho treat cell l amsn induc remark decreas level pro inflammatori cytokin tumor necrosi factor tnf interleukin il show therapeut potenti nanocarri base atv l amsn signific increas superoxid dismutas level decreas mda level indic superior anti inflammatori activ condit oxid stress l amsn show remark improv outer stripe outer medulla osom region maintain tubular structur kidney tissu besid kidney injuri score l amsn signific lower compar lps aki atv indic excel therapeut efficaci nanoparticul system base l amsn conclus nanoparticl system base l amsn maintain tubular structur kidney tissu indic excel therapeut efficaci clinic translat l amsn could serv promis treatment aki | D058186;D053758 | T047;T073;T037 |
34,688,319 | reconstruct nanohydroxyapatit prosthesi base ct scan data applic spinal injuri studi investig nanohydroxyapatit nha prosthesi applic effect base ct scan data spinal injuri studi chose spinal injuri patient treat hospit septemb septemb random divid two group nha prosthesi base ct scan data implant nha group wherea titanium mesh implant titanium mesh group consequ osteoblast cultur test biolog activ nha titanium alloy cell test found osteoblast could better adher nha prolifer activ higher plant nha materi surgic treatment patient spinal symptom vas score joa score cobb angl improv caus obvious inflammatori foreign bodi reaction two year follow fusion time support settlement nha group lower vertebr fusion rate asia score higher titanium mesh group thus ct scan data could improv vertebr fusion rate nha group consequenti nha prosthesi base ct scan data better choic spinal injuri therapi | D019736;D013124 | T074;T037 |
34,688,318 | notch mutat detect stroke patient select nanoliposom stroke allevi mous model studi analyz correl notch mutat stroke test effect nanoparticl load aspirin stroke therapi fifti patient ischem stroke follow two year fifti healthi person serv control group rt pcr studi reveal notch mutat exist ischem stroke patient like famili histori small vessel lesion relat frequent cerebr hemorrhag poor long term prognosi liposom aspirin chitosan nanoparticl lacn construct nano composit stroke treatment notch argci knock mice prepar mutant notch mous model test lacn infiltr effici observ anti stroke capac found lacn could better transport aspirin brain vessel polyethyleneimin pei deliveri system howev notch mutat mous model cerebr infarct hemorrhag often occur treat aspirin still lacn better prolong half life aspirin rescu patholog alter stroke brain reduc inflammatori reaction oxid stress respons conclus notch mutat close relat stroke occurr lacn may better choic stroke therapi futur | D002545;D046589;D020521 | T047;T046 |
34,688,317 | poli chitosan cis platinum conjug composit nanoparticl system liver cancer therapi aim studi test effect nano pole capsul load cis platinum cp transplant devic liver cancer lc therapi novel nano pole capsul design new vector store cp hepg cell bj mous model use test effici polyethyleneimin cis platinum pei cp poli chitosan cis platinum pc cp infiltr effici transplant effici test perform studi perform deliveri system fibroblast reaction macrophag number observ test immun reject foreign bodi reaction apoptosi rate tumor diamet hepatocellular carcinoma cell use evalu effect tumor therapi also studi function mechan differ cp deliveri system infiltr transplant effici pc cp higher pei cp less foreign bodi reaction appear pc system less fibroblast reaction lower macrophag reaction clinic efficaci pc cp term tumor apoptosi diamet reduct superior pei cp demonstr pc cp signific alter effect mtor p ak lc p pc system better deliv releas drug pei cp may better choic lc therapi futur | D048271;D008113;D053758;D004364 | T191;T121;T073;T109 |
34,688,316 | prepar properti thrombus target urokinasemulti wall carbon nanotub mwcnts chitosan cs rgd drug deliveri system order improv therapeut effect prolong action time reduc side effect first generat thrombolyt drug urokinas uk novel ukmulti wall carbon nanotub mwcnts chitosan cs arginin glycin aspart acid arg gli asp rgd drug deliveri system synthes chemic bondingnon coval bond modificationultrason dispers result show diamet ukmwcnt cs rgd drug deliveri system nm layer uk attach surfac tube wall distribut relat uniform averag encapsul effici averag drug load interest also certain sustain releas effect releas law best fit first order kinet equat moreov acceler long term stabil test result show good stabil compar free uk ukmwcnt cs rgd thrombolyt effect vitro addit mtt experi show prepar mwcnts cs rgd nanomateri good biocompat rabbit model carotid arteri thrombosi use conduct target thrombolysi experi vivo compar free uk ukmwcnt cs rgd could enrich thrombosi site achiev thrombus target ukmwcnt cs rgd drug deliveri system expect becom effect thrombolyt drug target therapi thrombosi | D048271;D037742;D013927 | T121;T073;T109;T046;T104 |
34,688,314 | updat distribut map predomin culex mosquito across america estim geograph distribut culex mosquito america limit state provinci level unit state canada base data sinc estim made mani document observ mosquito new method develop speci distribut model moreov mosquito distribut affect environment condit chang sinc call updat estim distribut understand risk emerg emerg mosquito born diseas | D063147 | T054 |
34,688,313 | driver global media attent represent antimicrobi resist risk analysi onlin english chines news media data antimicrobi resist amr risk communic news media shape public understand engag differ sector amr studi examin onlin news media attent amr risk analyz amr risk communic use global sampl english chines news articl | D004352;D007802;D008402 | T171;T072;T170;T032;T068 |
34,688,311 | knowledgepercept attitudepractic popul two first line communiti centr region cameroon regard onchocerciasi black fli nuisanc bio ecolog despit high black fli densiti persist onchocerciasi foci cameroon vector control ever carri complement communiti direct treatment ivermectin cdti prelud communiti base vector control studi explor knowledgepercept attitudepractic kap popul two first line communiti regard onchocerciasi black fli nuisanc bio ecolog | D007722;D011634 | T091;T053 |
34,688,307 | clinic cost effect self manag intervent patient persist depress disord partnerscaregiv studi protocol multicent pragmat random control trial regular treatment patient persist depress disord pdd may remain special psychiatr outpati care without achiev remiss lack option patient often receiv long term non protocol care usual cau involv partnercaregiv patient although revis depress treatment guidelin suggest focus psychiatr rehabilit self manag next treatment step pdd evid base cost effect self manag protocol pdd lack studi investig patient partner educ program chronic ill ppepal brief self manag protocol could lead lower cost higher qualiti life less diseas burden pdd patient partnerscaregiv | D003866;D000073278 | T058;T048 |
34,688,305 | metoclopramid induc acut dyston reaction case report acut dyston reaction caus drug uncommon daili practic whether outpati emerg set type unfavor reaction may caus treat physician work diagnosi misl certain point | D004421;D014060 | T047;T019;T184 |
34,688,304 | patient public involv randomis clinic trial mix method studi clinic trial unit identifi good practic barrier facilit patient public involv ppi clinic trial benefici mandat funder formal guidanc implement ppi limit challeng report aim investig ppi approach within uk clinic trial unit ctu portfolio randomis control trial perceiv barrier tofacilit success implement perspect ctu role ppi | D010358;D012108 | T058;T080;T097;T081 |
34,688,303 | nation survey pharmacist intern aotearoa new zealand provis view extend servic communiti pharmaci chang pharmaci model care servic fund occur intern move away tradit dispens role extend patient face role utilis pharmacist clinic skill studi aim identifi extend servic offer communiti pharmaci aotearoa new zealand barrier facilit extend servic provis studi uniqu includ intern pre registr pharmacist | D003157;D010594 | T058;T093;T073 |
34,688,302 | compar genom analysi colistin resist oxa produc klebsiella pneumonia clinic strain isol two iranian hospit carbapenemas produc klebsiella pneumonia cp kp becom extens dissemin iranian medic center colistin among agent retain activ cp kp howev administr colistin treatment carbapenem resist infect increas resist antibiot therefor identif genet background co carbapenem colistin resist k pneumonia co ccrkp urgent implement serious infect control strategi | D001618 | T116;T126 |
34,688,300 | hospit covid infect echocardiograph analysi brazilian tertiari singl centr experi inform lack concern hospit echocardiographi analysi covid infect brazil evalu echocardiograph paramet predict composit endpoint mortal pulmonari thromboembol acut renal failur | D000086382 | T047;T067 |
34,688,299 | develop therapi rare genet disord gpx roadmap opportun extrem rare progress diseas like sedaghatian type spondylometaphys dysplasia ssmd neonat lethal therefor go undiagnos difficult treat recent sequenc effort link diseas mutat gpx consequ result enzym glutathion peroxidas offer potenti diagnost therapeut avenu suffer diseas though step toward treatment often convolut expens time consum | D010009;D035583 | T047;T019 |
34,688,298 | comprehens character intern cuticl surfac microbiota laboratori rear f anophel albimanus origin differ site research mosquito microb interact may lead new tool mosquito mosquito born diseas control date research larg util laboratori rear mosquito typic lack microbi divers wild popul logic progress area involv work control set use field collect mosquito case progeni thus understand laboratori colon affect assemblag mosquito microbiota would aid advanc mosquito microbiom studi applic beyond laboratori set | D064307 | T032;T001;T028 |
34,688,297 | adapt design web base decis support clinic trial covid pandem public health crise emerg covid pandem signific impact provis medic care place sudden restrict ongo clinic research patient face clinic research confront uniqu challeng recruit studi protocol halt adapt meet safeti procedur pandem studi protocol includ use lung cancer screen decis tool lcsdectool context primari care visit consider impact pandem describ experi adapt multi site clinic trial lcsdectool within depart veteran affair health care system conduct random control trial rct compar lcsdectool control intervent outcom includ lung cancer screen lcs knowledg share decis make uptak adher lcs protocol identifi three strategi led success adapt studi design pandem multi level coordin communic across organ studi site flexibl adapt research time uncertainti chang regul leverag technolog deliv intervent conduct studi visit rais issu concern equiti intern extern valid | D000086382;D058873 | T047;T067 |
34,688,296 | understand multidisciplinari care peopl rheumat diseas british columbia canada patient nurs physician voic qualit polici evalu provinc british columbia bc move allow patient complex rheumat diseas seen nurs along rheumatologist introduc multidisciplinari care assess mca bill code g | D009726;D010820;D012216 | T097;T047 |
34,688,295 | compar covid physic distanc polici result physic distanc intens code framework botswana india jamaica mozambiqu namibia ukrain unit state understand differ time composit physic distanc polici import evalu earli global respons covid physic distanc intens monitor framework compris domain recent publish compar physic distanc approach across us state appli framework divers set low middl incom countri lmic botswana india jamaica mozambiqu namibia ukrain test appropri framework global context compar polici respons lmic sampl us state first day pandem | D000086382 | T047;T067 |
34,688,292 | sequenti drug deliveri inject macropor hydrogel combin photodynam chemotherapi hollow mesopor silica hmsn inject macropor hydrogel gel use intern extern drug load materi respect sequenti drug deliveri system dox cap gel construct combretastatin phosphat cap doxorubicin dox load anti angiogen drug cap initi releas due degrad gel follow anti cell prolif drug dox releas hmsn tumor microenviron result show cap main releas earli stage h cap releas reach dox h cap dox releas signific increas show obvious sequenti releas behavior photodynam properti porphyrin endow hydrogel gel enhanc tumor therapi effect vitro vivo experi show dual drug treat group better tumor inhibit solo drug near infrar laser irradi indic effect combin photodynam chemotherapi | D004317;D013267 | T195;T121;T109 |
34,688,291 | initi trial protocol random control trial test effect quit card intervent long term abstin among tobacco smoker present emerg depart smoke cessat intervent implement emerg depart ed set result limit success owe factor lack time motiv incent dynam yet simpl effect approach address fast pace natur acut care ed set need studi propos multi center random control trial rct compar effect easi deliv proactiv multi compon tobacco treatment intervent usual care ed set | D000074285;D016540 | T033;T098;T055 |
34,688,290 | psychometr properti itch numer rate scale skin pain numer rate scale atop dermat sleep scale adult patient moder sever atop dermat itch numer rate scale nrs skin pain nrs atop dermat sleep scale adss self administ patient report outcom pro instrument develop assess symptom patient atop dermat ad object studi evalu psychometr properti reliabl valid respons interpret threshold pros use data three pivot phase studi adult | D003876 | T047 |
34,688,288 | self report knowledg attitud practic barrier use evid base medicin among resid physician kenya mix method studi evid base medicin ebm help clinician integr latest research evid daili clinic practic need healthcar profess adopt order provid safe cost effect care postgradu doctor frontlin healthcar deliveri medic institut strive produc practition ebm studi shown physician still struggl adapt paradigm shift practic medicin studi done sub saharan africa studi explor self report knowledg attitud practic barrier evid base practic among resid physician tertiari teach hospit | D007722;D010820 | T097;T053 |
34,688,287 | complex involv implement challeng result process analysi studi object analys implement challeng experienc carri improv programm programm design implement checklist relat improv initi base nation periop guidelin use step wedg trial design process analysi carri investig involv implement activ | D006761;D012107 | T073;T170;T169;T062;T093;T081;T096 |
34,688,286 | sonograph patholog featur metaplast squamous cell carcinoma breast case seri aim studi evalu sonograph featur compar sonograph find patholog featur | D001943;D002294 | T191 |
34,688,285 | insecticid treat eav ribbon malaria vector control low incom communiti supplementari tool requir address limit insecticid treat net itn indoor residu spray ir current core vector control method malaria africa eav ribbon technolog exploit natur hous entri behaviour major malaria vector deliv mosquitocid repel activ around eav space anophel mosquito usual enter human dwell confer protect prevent bite indoor peri domest outdoor space also kill signific proport mosquito current version eav ribbon made low cost hessian fabric infus candid insecticid easili fit onto multipl hous type without addit modif articl review evid efficaci technolog discuss potenti afford versatil supplementari approach target effici control mosquito born diseas particular malaria given simplic demonstr potenti previous studi futur research investig way optim scalabl effect ribbon also import assess whether ribbon may constitut less cumbersom afford substitut intervent ir judici use lower quantiti select insecticid target around eav space deliv equival greater suppress malaria transmiss | D000852;D006798;D007306;D009032;D000072138 | T131;T204;T057;T073 |
34,688,284 | estim global number e cigarett user combust tobacco main caus tobacco relat morbid mortal e cigarett potenti disrupt innov consider potenti popul health key question whether e cigarett replac tobacco cigarett requir map preval collect inform nicotin use difficult mani countri due cost object studi deriv global estim e cigarett use vape | D066300;D062789;D000072137 | T055;T131;T073;T109 |
34,688,283 | statist analysi plan earli youth engag first episod psychosi eye studi pragmat cluster randomis control trial implement effect cost effect team base motiv engag intervent improv engag earli intervent psychosi eip servic improv health outcom young peopl psychosi medium long term young peopl disengag first month cost mental health famili societi health servic studi evalu effect team base motiv engag intervent earli youth engag eye intervent | D011618;D011788 | T048;T078 |
34,688,282 | differ outcom hospit heart failur sglt inhibitor treatment effect modif atherosclerot cardiovascular diseas treatment effect hospit heart failur hhf sodium glucos cotransport sglt inhibitor may vari among type diabet td patient depend whether establish atherosclerot cardiovascular diseas ascvd aim examin differ hhf outcom dapagliflozin empagliflozin use td patient without histori establish ascvd | D006760 | T058 |
34,688,281 | scale physic activ everyon pae intervent secondari school month implement cost outcom cluster randomis control trial physic activ everyon pae evid base program effect increas adolesc physic activ pa improv weight status studi aim determin effect adapt implement intervent scale pae month follow b fidel reach c cost cost effect implement support intervent | D006293;D012572 | T058;T170 |
34,688,280 | associ left ventricular longitudin myocardi function subclin right ventricular dysfunct type diabet mellitus left ventricular lv involv diabet cardiomyopathi report howev limit data exist right ventricular rv involv therefor purpos investig rv systol dysfunct associ lv longitudin myocardi dysfunct patient type diabet mellitus tdm preserv lv eject fraction lvef | D016277;D016278 | T042 |
34,688,279 | confront complex support transform health system map case studi health system complex web interact interconnect part introduc intervent alloc resourc one sector effect across sector impact entir system prerequisit effect health system reorganis transform broad common understand current system amongst stakehold innov chronic obstruct pulmonari diseas copd heart failur hf common chronic diseas high health care cost requir integr health system effect treat | D017753;D029424 | T070;T082;T047 |
34,688,278 | citizen scienc base survey avian mortal focus haemosporidian infect wild passerin bird haemosporidios common bird manifest rang subclin infect sever diseas depend involv parasit bird speci clinic haemosporidios often observ non adapt zoo aviari bird wherea wild bird particular passerin haemosporidian infect frequent seem asymptomat howev recent studi austria show pathogen haemosporidian infect common blackbird due high parasit burden plasmodium matutinum linn common parasit bird speci suggest virul infect also occur natur host base find present studi aim explor whether extent nativ bird speci possibl affect pathogen haemosporidian lineag contribut avian morbid | D000080029;D020308 | T062;T012 |
34,688,277 | chang childhood experiment exposur tobacco e cigarett perceiv smoke norm repeat cross section studi year old wale today primari school children grown climat strong smoke restrict decreas tobacco use emerg e cigarett children exposur tobacco declin substanti year follow introduct smoke free legisl smoke uptak perceiv smoke norm declin debat regard whether emerg e cigarett may interrupt trend children smoke percept offer mean adult limit children exposur tobacco studi examin chang children tobacco e cigarett experiment ever use exposur secondhand smoke vape perceiv smoke norm | D066300;D062789;D014028;D000072137 | T073;T109;T055;T131;T033;T069 |
34,688,276 | ten gene base diagnost signatur atherosclerosi atherosclerosi lead caus cardiovascular diseas high mortal worldwid understand atherosclerosi pathogenesi identif effici diagnost signatur remain major problem modern medicin studi aim screen potenti diagnost gene atherosclerosi | D053263 | T044 |
34,688,275 | associ overweight gestat diabet mellitus free sugar solid liquid sourc cross section nest case control analys sugar sweeten beverag obesogen diabetogen effect ascrib free sugar includ ad sugar natur occur sugar juic meta analysi indic food ad sugar associ lower type diabet rate expand evid relev free sugar solid sourc examin young middl age popul respect overweight gestat diabet gdm outcom | D003924;D016640 | T047 |
34,688,274 | long read sequenc base silico phage type vancomycin resist enterococcus faecium vancomycin resist enterococci vre success nosocomi pathogen abl caus hospit outbreak netherland core genom mlst cgmlst base short read sequenc often use molecular type long read sequenc rapid provid use inform genom structur composit lack precis requir snp base type cgmlst compar prophag among complet e faecium genom belong differ lineag explor whether phage signatur would usabl type identifi outbreak caus vre proof principl investig long read sequenc data would allow identifi phage signatur therebi outbreak relat isol | D003428;D016984;D016908;D065507 | T007;T047 |
34,688,273 | studi protocol non randomis communiti trial evalu effect communiti care prevent system germani communiti care ctc prevent plan implement system train communiti throughout five phase cycl build capac prevent adopt scienc base prevent assess prevent need adolesc live communiti select implement evid base program accord need ctc prove effect cost effect us use increas number communiti germani aim studi evalu effect cost effect ctc germani | D019966 | T033;T048 |
34,688,272 | build biopsychosoci model cancer relat fatigu biocar factori cohort studi protocol cancer relat fatigu crf common side effect cancer cancer treatment crf preval breast cancer patient continu sever year cancer remiss persist subject sens exhaust multifactori numer paramet evidenc relat crf across biolog physic psycholog social andor behavior dimens although crf studi mani year major previous studi focus one dimens ie physic function moreov studi investig crf longitudin repeat measur two main obstacl limit understand crf mechan purpos studi creat biopsychosoci model crf simultan longitudin anthropometr clinic biolog physic psycholog sociolog paramet | D000071066 | T170 |
34,688,271 | psycholog respons associ factor initi stage coronavirus diseas covid epidem among adult popul poland cross section studi studi aim assess emot state occurr symptom depress anxieti stress well qualiti life adult live poland first week covid pandem | D000086382;D058873 | T047;T067 |
34,688,270 | bacteri vaginosi infect pregnant women seneg bacteri vaginosi bv associ higher risk preterm deliveri spontan abort yet littl data bv preval exist sub saharan countri aim studi estim preval bacteri vaginosi associ risk factor among pregnant women seneg | D011251;D016585 | T047 |
34,688,268 | european agroforestri unequivoc effect biodivers time cumul meta analysi agroforestri product system combin tree crop livestock potenti increas biodivers relat singl use system pastur cropland provid higher habitat heterogen literatur review subsequ meta analysi investig relationship biodivers agroforestri critic apprais under evid result | D044822;D014197 | T080;T002 |
34,688,267 | map geograph cluster new hiv diagnos inform granular level intervent hiv epidem control western kenya countri make progress toward hiv epidem control increas need identifi finer geograph area target hiv intervent map geograph cluster new hiv diagnos describ factor associ hiv posit diagnosi order inform target hiv intervent finer geograph area sub popul | D058872;D015658 | T047;T067 |
34,688,266 | econom evalu patient cost associ tuberculosi diagnosi care solomon island tuberculosi tb care cost patient famili end tb strategi includ target zero tb affect household experi catastroph cost associ tb care cost catastroph patient spend annual household incom tb diagnosi care solomon island cost tb care unknown aim studi determin cost tb diagnosi care type cost proport patient catastroph cost | D017048;D014376 | T047;T081 |
34,688,265 | social particip associ good self rate health among visual impair older adult jage cross section studi recogn visual impair associ poor self rate health srh addit various negat health outcom visual impair number older adult visual impair increas due popul age increas evid found effect social particip good srh examin whether associ social particip srh investig whether effect differ visual status | D006304;D058992 | T080;T054 |
34,688,263 | predict patholog respons neoadjuv chemotherapi patient local advanc breast cancer use multiparametr mri studi aim observ analyz effect diffus weight magnet reson imag mri patient local advanc breast cancer undergo neoadjuv chemotherapi | D000081364 | T060 |
34,688,262 | long term surviv patient microsatellit stabl refractori colorect cancer regorafenib pd inhibitor sintilimab case report review literatur colorect cancer crc third preval cancer worldwid pose serious challeng clinician previous studi shown promis result patient microsatellit stabl microsatellit stabl crc refractori chemotherapi upon treat program cell death protein pd inhibitor combin regorafenib herein report uniqu case patient convent chemotherapi radiotherapi ineffect show prolong stabl diseas third line treatment regorafenib pd inhibitor sintilimab | D015179;D000082082 | T043;T191;T121;T129 |
34,688,261 | serum ca diagnosi pulmonari tuberculosi systemat review meta analysi pulmonari tuberculosi ptb remain world deadliest infecti killer serum ca test use diagnosi ptb although studi relat ca ptb report specif sensit serum ca diagnos ptb vari wide among differ studi present studi perform evalu accuraci ca diagnosi ptb via meta analysi data obtain previous studi | D014397 | T047 |
34,688,259 | tenosynov caus mycobacterium marseillens initi identifi mycobacterium avium complex use accuprob coba taqman mycobacterium marseillens new speci mycobacterium avium complex human infect caus marseillens worldwid | D009161;D015270;D013717 | T007;T047 |
34,688,258 | genom wide associ analys carcass trait use copi number variant raw intens valu singl nucleotid polymorph cattl carcass valu cattl function carcass weight qualiti given econom import carcass merit produc routin includ beef breed object detail understand genet variant contribut carcass merit use maxim effici breed improv carcass merit object present studi two fold first perform genom wide associ analys carcass weight carcass conform carcass fat use copi number variant cnv data popul holstein friesian charolai limousin bull second perform separ associ analys carcass trait popul cattl use log r ratio lrr valu singl nucleotid polymorph snps lrr valu snp measur signal intens snp generat genotyp process | D055106;D020641 | T086;T063 |
34,688,255 | socio demograph econom factor associ day readmiss condit target hospit readmiss reduct program popul base studi earli hospit readmiss remain common patient condit target cms hospit readmiss reduct program hrrp still consensus whether readmiss measur adjust base social factor popul studi within us examin social characterist influenc readmiss hrrp target condit object studi determin specif socio demograph econom factor associ day readmiss hrrp target condit acut exacerb chronic obstruct pulmonari diseas pneumonia acut myocardi infarct heart failur | D006333;D010359 | T058;T047;T046 |
34,688,254 | feasibl accept peer youth led curriculum improv hiv knowledg northern tanzania resili intervent experi perspect peer leader youth live hiv ylwh reduc adher antiretrovir therapi art wors virolog outcom compar children adult hiv peer youth led pyl intervent contribut improv retent care psychosoci wellb studi object assess feasibl accept pyl hiv curriculum describ chang particip knowledg impact leadership peer leader live | D015658 | T047 |
34,688,253 | differ gray matter volum episod migrain patient without prior diagnosi clinic care cross section studi migrain suffer face difficulti get appropri care treatment migrain associ reduc gray matter volum gmv sever brain region could relat various clinic characterist disord | D066128;D008881 | T047;T023;T024 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.